Future oncology (London, England) · 2019
Patient preferences for treatment of metastatic melanoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mansfield Carol, Ndife Briana, Chen Joyce, Gallaher Kathleen, Ghate Sameer
Аннотация
AIM: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments.
MATERIALS & METHODS: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes.
RESULTS: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant.
CONCLUSION: Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.
MATERIALS & METHODS: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes.
RESULTS: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant.
CONCLUSION: Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.